# US 2006/0135411 A1 · Treatment of inflammatory bowel disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0135411 A1
- Document ID: US20060135411A1
- Status: Published application
- Kind: A1
- Application number: 10/531,564
- Filed: 2003-10-15
- Published: 2006-06-22
- Earliest claimed: 2002-10-16
- Assignees: The University of Queensland
- Inventors: Trent Woodruff; Steven Taylor; David Fairlie
- Web page: https://patentgrep.com/patent/US20060135411A1

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to methods of treatment of inflammatory bowel disease, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the methods of the invention are disclosed.

## Claims

### Claim 1

A method of treatment of inflammatory bowel disease, comprising the step of administering an effective amount of an inhibitor of a G protein-coupled receptor to a subject in need of such treatment, in which the inhibitor is a compound which
(a) is an antagonist of a G protein-coupled receptor,
(b) has substantially no agonist activity, and
(c) is a cyclic peptide or peptidomimetic compound of formula I
where A is H, alkyl, aryl, NH2, NH-alkyl, N(alkyl)2, NH-aryl, NH-acyl, NH-benzoyl, NHSO3, NHSO2-alkyl, NHSO2-aryl, OH, O-alkyl, or O-aryl;
B is an alkyl, aryl, phenyl, benzyl, naphthyl or indole group, or the side chain of a D- or L-amino acid, but is not the side chain of glycine, D-phenylalanine, L-homophenylalanine, L-tryptophan, L-homotryptophan, L-tyrosine, or L-homotyrosine;
C is the side chain of a D-, L- or homo-amino acid, but is not the side chain of isoleucine, phenylalanine, or cyclohexylalanine;
D is the side chain of a neutral D-amino acid, but is not the side chain of glycine or D-alanine, a bulky planar side chain, or a bulky charged side chain;
E is a bulky substituent, but is not the side chain of D-tryptophan, L-N-methyltryptophan, L-homophenylalanine, L-2-naphthyl L-etrahydroisoquinoline, L-cyclohexylalanine, D-leucine, L-fluorenylalanine, or L-histidine;
F is the side chain of L-arginine, L-homoarginine, L-citrulline, or L-canavanine, or a bioisostere thereof; and
X is —(CH2)nNH— or (CH2)n—S—, where n is an integer of from 1 to 4; —(CH2)2O—; —(CH2)3O—; —(CH2)3—; —(CH2)4—; —CH2COCHRNH—; or —CH2—CHCOCHRNH—, where R is the side chain of any common or uncommon amino acid.

### Claim 2 (depends on 1)

A method according to claim 1, in which n is 2 or 3.

### Claim 3 (depends on 1)

A method according to claim 1, in which A is an acetamide group, an aminomethyl group, or a substituted or unsubstituted sulphonamide group.

### Claim 4 (depends on 1)

A method according to claim 1, in which A is a substituted sulphonamide, and the substituent is an alkyl chain of 1 to 6 carbon atoms, or a phenyl or toluyl group.

### Claim 5 (depends on 4)

A method according to claim 4, in which the substituent is an alkyl chain of 1 to 4 carbon atoms.

### Claim 6 (depends on 1)

A method according to claim 1, in which B is the side chain of L-phenylalanine or L-phenylglycine.

### Claim 7 (depends on 1)

A method according to claim 1, in which C is the side chain of glycine, alanine, leucine, valine, proline, hydroxyproline, or thioproline.

### Claim 8 (depends on 1)

A method according to claim 1, in which D is the side chain of D-Leucine, D-homoleucine, D-cyclohexylalanine, D-homocyclohexylalanine, D-valine, D-norleucine, D-homo-norleucine, D-phenylalanine, D-tetrahydroisoquinoline, D-glutamine, D-glutamate, or D-tyrosine.

### Claim 9 (depends on 1)

A method according to claim 1, in which E is the side chain of an amino acid selected from the group consisting of L-phenylalanine, L-tryptophan and L-homotryptophan, or is L-1-napthyl or L-3-benzothienyl alanine.

### Claim 10 (depends on 1)

A method according to claim 1, in which the inhibitor is a compound which has antagonist activity against C5aR, and has no C5a agonist activity.

### Claim 11 (depends on 1)

A method according to claim 1, in which the inhibitor has potent antagonist activity at sub-micromolar concentrations.

### Claim 12 (depends on 1)

A method according to claim 1, in which the compound has a receptor affinity IC50<25 μM, and an antagonist potency IC50□|μ{tilde over (□)}

### Claim 13 (depends on 1)

A method according to claim 1, in which the compound is selected from the group consisting of compounds 1 to 6, 10 to 15, 17, 19, 20, 22, 25, 26, 28, 30, 31, 33 to 37, 39 to 45, 47 to 50, 52 to 58 and 60 to 70 described in PCT/AU02/01427.

### Claim 14 (depends on 13)

A method according to claim 13, in which the compound is PMX53 (compound 1), compound 33, compound 60 or compound 45 described in PCT/AU02/01427.

### Claim 15 (depends on 1)

A method according to claim 1, in which the inhibitor is used in conjunction with one or more other agents for the treatment of inflammatory bowel disease.

### Claim 16 (depends on 15)

A method according to claim 15, in which the other agent is infliximab or is an inhibitor of C3a.

### Claim 17 (depends on 1)

A method according to claim 1, in which the treatment is to prevent or alleviate acute recurrences of inflammatory bowel disease.

### Claim 18 (depends on 1)

A method according to claim 1, in which the treatment is to prevent or alleviate a primary occurrence of inflammatory bowel disease.

### Claim 19 (depends on 1)

A method according to claim 1, in which the inflammatory bowel disease is selected from the group consisting of ulcerative colitis, Crohn's disease, lymphocytic-plasmocytic enteritis, coeliac disease, collagenous colitis, lymphocytic colitis and eosinophilic enterocolitis, indeterminate colitis, infectious colitis, pseudomembranous colitis (necrotizing colitis), and ischemic inflammatory bowel disease.

### Claim 20 (depends on 1)

A method according to claim 1, in which the inflammatory bowel disease is ulcerative colitis.

### Claim 21 (depends on 1)

A method according to claim 1, in which the inflammatory bowel disease is Crohn's disease.

### Claim 22 (depends on 1)

A method according to claim 1, in which the inflammatory bowel disease is selected from the group consisting of enterocolitis, canine plasmacytic-lymphocytic colitis, protothecal colitis, and histocytic ulcerative colitis.

### Claim 23 (depends on 1)

A method according to claim 1, in which the inhibitor is administered in an enteric coated capsule or per-rectally.
